Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults

[1]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[2]  J. Kim,et al.  INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants , 2021, bioRxiv.

[3]  Y. Sung,et al.  Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates , 2021, Vaccines.

[4]  T. de Oliveira,et al.  New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications , 2021, The New England journal of medicine.

[5]  D. Prazeres,et al.  mRNA vaccines manufacturing: Challenges and bottlenecks , 2021, Vaccine.

[6]  L. Morris,et al.  SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, Nature Medicine.

[7]  E. Wherry,et al.  CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer , 2021, Research square.

[8]  Jincun Zhao,et al.  Mapping and role of T cell response in SARS-CoV-2–infected mice , 2021, The Journal of experimental medicine.

[9]  Thamer Alshammari,et al.  Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2 , 2021, Pharmaceuticals.

[10]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[11]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[12]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.

[13]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[14]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[15]  G. Matarese,et al.  T Cells: Warriors of SARS-CoV-2 Infection , 2020, Trends in Immunology.

[16]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[17]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.

[18]  E. Walsh,et al.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.

[19]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[20]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[21]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[22]  James T. Gordy,et al.  The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development , 2020, Journal of Virology.

[23]  Lei S. Qi,et al.  Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza , 2020, Cell.

[24]  Jae Kwan Lee,et al.  A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3 , 2019, Clinical Cancer Research.

[25]  Shixia Wang,et al.  DNA Immunization , 2013, Current protocols in microbiology.